# Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

> **NCT00687765** · PHASE1,PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 126 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** bsi-201 plus temozolomide

## Key facts

- **NCT ID:** NCT00687765
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687765, "Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00687765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*